Below are the most recent publications written about "Alemtuzumab" by people in Profiles.
-
Gooptu M, Kim HT, Jacobsen E, Fisher DC, LaCasce A, Ho VT, Cutler CS, Koreth J, Soiffer RJ, Antin JH, Berliner N, Nikiforow S. Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis. Blood Adv. 2023 06 13; 7(11):2309-2316.
-
Kiapour N, Wu B, Wang Y, Seyedsadr M, Kapoor S, Zhang X, Elzoheiry M, Kasimoglu E, Wan Y, Markovic-Plese S. Therapeutic Effect of Anti-CD52 Monoclonal Antibody in Multiple Sclerosis and Its Animal Models Is Mediated via T Regulatory Cells. J Immunol. 2022 07 01; 209(1):49-56.
-
Santos AH, Leghrouz MA, Bueno EP, Andreoni KA. Impact of antibody induction on the outcomes of new onset diabetes after kidney transplantation: a registry analysis. Int Urol Nephrol. 2022 Mar; 54(3):637-646.
-
Brown M, Abasov R, Salerno D, Shore TB, Gergis U, Mayer S, Phillips A, Hsu J, Kodiyanplakkal RPL, Pasciolla M, van Besien K. Impact of alemtuzumab dosing and low-dose total body irradiation on cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2020 12; 61(12):3024-3026.
-
Braunstein Z, Mishra A, Staub A, Freud AG, Porcu P, Brammer JE. Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response. Br J Haematol. 2021 02; 192(3):484-493.
-
Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Ahmed I, Aljurf M, Askar M, Auletta JJ, Bhatt V, Bredeson C, Chhabra S, Gadalla S, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Inamoto Y, Kitko C, Khandelwal P, MacMillan ML, Majhail N, Marks DI, Mehta P, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Qayed M, Rangarajan H, Ringden O, Saad A, Savani BN, Seo S, Shah A, Shah N, Schultz KR, Solh M, Spitzer T, Szer J, Teshima T, Verdonck LF, Williams KM, Wirk B, Wagner J, Yared JA, Weisdorf DJ. GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Adv. 2019 05 14; 3(9):1441-1449.
-
Zhang M, Wen B, Anton OM, Yao Z, Dubois S, Ju W, Sato N, DiLillo DJ, Bamford RN, Ravetch JV, Waldmann TA. IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages. Proc Natl Acad Sci U S A. 2018 11 13; 115(46):E10915-E10924.
-
Brooks JT, Mitro G, DeLeonibus A, Qu W, Rees M, Nazzal M, Ortiz J. Alemtuzumab Induction Is Associated With an Equalization of Outcomes Between White and African American Kidney Transplant Recipients. Exp Clin Transplant. 2019 04; 17(2):196-201.
-
Koyawala N, Silber JH, Rosenbaum PR, Wang W, Hill AS, Reiter JG, Niknam BA, Even-Shoshan O, Bloom RD, Sawinski D, Nazarian S, Trofe-Clark J, Lim MA, Schold JD, Reese PP. Comparing Outcomes between Antibody Induction Therapies in Kidney Transplantation. J Am Soc Nephrol. 2017 Jul; 28(7):2188-2200.
-
Schmidt K, Kleinschnitz K, Rakocevic G, Dalakas MC, Schmidt J. Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM. BMC Neurol. 2016 Apr 16; 16:48.